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Abstract
Background: We established Safeguard the Family (STF) to support Ministry of Health (MoH) scale-up of universal
antiretroviral therapy (ART) for HIV-infected pregnant and breastfeeding women (Option B+) and to strengthen the
prevention of mother-to-child transmission (PMTCT) cascade from HIV testing and counseling (HTC) through
maternal ART provision and post-delivery early infant HIV diagnosis (EID). To these ends, we implemented the
following interventions in 5 districts: 1) health worker training and mentorship; 2) couples’ HTC and male partner
involvement; 3) women’s psychosocial support groups; and 4) health and laboratory system strengthening for EID.
Methods: We conducted a serial cross-sectional study using facility-level quarterly (Q) program data and individual-
level infant HIV-1 DNA PCR data to evaluate STF performance on PMTCT indicators for project years (Y) 1
(April—December 2011) through 3 (January—December 2013), and compared these results to national averages.
Results: Facility-level uptake of HTC, ART, infant nevirapine prophylaxis, and infant DNA PCR testing increased
significantly from quarterly baselines of 66 % (n/N = 32,433/48,804), 23 % (n/N = 442/1,958), 1 % (n/N = 10/1,958),
and 52 % (n/N = 1,385/2,644) to 87 % (n/N = 39,458/45,324), 96 % (n/N = 2,046/2,121), 100 % (n/N = 2,121/2,121),
and 62 % (n/N = 1,462/2,340), respectively, by project end (all p < 0.001). Quarterly HTC, ART, and infant nevirapine
prophylaxis uptake outperformed national averages over years 2–3. While transitioning EID laboratory services to
MoH, STF provided first-time HIV-1 DNA PCR testing for 2,226 of 11,261 HIV-exposed infants (20 %) tested in the
MoH EID program in STF districts from program inception (Y2) through Y3. Of these, 78 (3.5 %) tested HIV-positive.
Among infants with complete documentation (n = 608), median age at first testing decreased from 112 days
(interquartile range, IQR: 57–198) in Y2 to 76 days (IQR: 46–152) in Y3 (p < 0.001). During Y3 (only year with national
data for comparison), non-significantly fewer exposed infants tested HIV-positive (3.6 %) at first testing in STF
districts than nationally (4.1 %) (p = 0.4).
Conclusions: STF interventions, integrated within the MoH Option B+ program, achieved favorable HTC, maternal
ART, infant prophylaxis, and EID services uptake, and a low proportion of infants found HIV-infected at first DNA
PCR testing. Continued investments are needed to strengthen the PMTCT cascade, particularly around EID.
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Background
Malawi is a low-income sub-Saharan Africa (SSA)
country heavily burdened by HIV/AIDS, with an adult
HIV prevalence of 10.3 % [1]. The Malawi epidemic
disproportionately affects women who comprise 59 %
of prevalent cases [1]. Consequently, 68,000 neonates
are exposed to HIV and 11,000 infants become newly
HIV-infected each year, adding to the 100,000 preva-
lent cases of pediatric HIV/AIDS nationally [2]. With-
out timely HIV diagnosis, treatment, and care, half of these
children will die before their second birthday [3].
Prevention of mother-to-child transmission (PMTCT) in-
terventions are the most effective way to halt HIV acquisi-
tion among infants and children in SSA [4]. As PMTCT
interventions, including improved HIV testing strategies,
maternal combination antiretroviral therapy (ART), and
infant nevirapine prophylaxis have become more widely
available, marked reductions in mother-to-child HIV trans-
mission (MTCT) throughout the perinatal period have
been observed—from a baseline of 20-45 % over a decade
ago to less than 5 % under research conditions in the ART
era [4–6]. Such reductions may be realized when HIV pre-
vention and treatment interventions are optimized for
HIV-infected mothers and their HIV-exposed infants at
each step of the PMTCT cascade—from HIV testing and
counseling (HTC) and maternal ART initiation through in-
fant nevirapine prophylaxis provision, early infant HIV
diagnosis (EID), and maternal-infant follow-up until breast-
feeding cessation [7, 8].
Under real-world conditions in resource-limited settings
a variety of factors attenuate the effectiveness of PMTCT
interventions, including resource limitations, inadequate
laboratory capacity, health system inefficiencies, and client
loss-to-follow-up [9, 10]. Predictive modeling using data
from South Africa, Uganda, and Malawi have estimated
that the risk of MTCT remains high in real-world settings,
approaching 20 % in programs using short-course ART
[11]. In Malawi, as recently as 2010, fewer than half of all
HIV-infected pregnant women received any PMTCT
intervention, and as many as 14 % of exposed infants were
found HIV-infected by early DNA PCR testing [12, 13].
In response to these challenges, in September 2011
the Malawi Ministry of Health (MoH) introduced the
pioneering “Option B+” strategy of “test and treat,”
lifelong combination ART for all HIV-infected preg-
nant and breastfeeding women [14, 15]. In only its first
year, the MoH reported a dramatic increase in the
number of HIV-infected pregnant and breastfeeding
women accessing ART for their own health and to re-
duce MTCT. Indeed, the number of pregnant and breast-
feeding women initiating ART increased 748 % with the
introduction of Option B+ compared to baseline, resulting
in greater population-level ART coverage for HIV-infected
women [14, 16]. However, despite these impressive gains,
client refusal of ART and dropout from the PMTCT
cascade threaten the effectiveness of Option B+ in Malawi.
As many as 15 % and 17 % of Option B+ clients, respect-
ively, either do not start ART or become lost to follow-up
within 6 months of ART initiation [10, 17]. Such early
client drop-out from the PMTCT cascade has deleterious
“downstream” effects, as inefficiencies in antenatal PMTCT
service delivery manifest as obstacles to diagnosis,
treatment, and care further along the cascade, ultim-
ately resulting in higher MTCT risk [11].
For over a decade, the University of North Carolina
Project—Malawi (UNC) has provided services and
conducted research to strengthen the PMTCT cascade
in Malawi’s capital, Lilongwe [18–24]. With MoH support
and in response to our funder’s request to translate
evidence into programmatic action, from April 2011
through December 2013 UNC expanded its PMTCT
program beyond Lilongwe to include five districts in
central Malawi (Lilongwe, Dedza, Ntcheu, Mchinji,
and Dowa districts), creating the Safeguard the Family
(STF) project.
STF had two main objectives: 1) reduce MTCT in the
project catchment area; and 2) increase access to high-
quality HIV services, including HTC, maternal combination
ART (via Option B+), infant nevirapine prophylaxis, and
early infant HIV-1 DNA PCR testing, for pregnant women
and their HIV-exposed infants during the antenatal and im-
mediate postnatal periods (Fig. 1). In this study, we aim to
assess the impact of STF interventions by evaluating
STF project outcomes over time and compared to na-
tional averages, and by estimating HIV prevalence
among HIV-exposed infants at first HIV-1 DNA PCR
testing. We also describe the STF implementation model
and discuss promising strategies to mitigate barriers to
service delivery along the early PMTCTcascade in SSA.
Methods
Ethics statement
The National Health Sciences Research Committee of
Malawi and the Institutional Review Board of the Uni-
versity of North Carolina, USA, granted ethical approval
for all project evaluation elements described herein
without requiring patient consent given the retrospective
use of de-identified, routinely collected programmatic
and clinical data.
Malawi National PMTCT Program overview
Since 2002, the MoH has offered free PMTCT services,
including HTC and anti-retroviral medications, to HIV-
infected pregnant women as part of the National ART
Program. From 2007 through August 2011—a period
encompassing the first 5 months of STF—the National
PMTCT Program provided AZT-combination prophylaxis
as the standard of care. This prophylactic regimen included,
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for mothers, daily AZT (beginning in the 28th week of
pregnancy) followed by single-dose nevirapine (SD-NVP)
plus AZT/3TC at labor onset and a post-delivery 1-week
AZT/3TC tail, and, for infants, SD-NVP plus 1 to 4 weeks
of AZT syrup (with infant AZT course determined by the
duration of maternal prophylaxis) [25]. With the intro-
duction of Option B+ in September 2011, the recom-
mended PMTCT regimen changed to universal, life-
long, fixed-dose combination efavirenz, lamivudine,
and tenofovir for mothers, and 6 weeks of nevirapine
prophylaxis for infants [26].
Malawi MoH Option B+ program overview
The MoH Option B+ program takes a public-health
approach to PMTCT, and provides the following services
as the national standard of care: 1) integrated opt-out
HTC and ART services in all ANC clinics, with same-day
ART availability for all HIV-infected pregnant women; 2)
repeat HTC for women testing negative more than
3 months prior to returning for any health service, includ-
ing antenatal and obstetrical care; 3) nevirapine syrup pro-
vided to HIV-infected mothers during antenatal care
(ANC) for infant prophylaxis; and 4) provision of a one-
pill, once-per-day combination ART regimen.[14] The
MoH Option B+ program encompasses EID services. The
MoH EID program provides HIV-exposed infants with
early registration and longitudinal follow-up in the MoH
HIV Care Clinic (HCC), co-trimoxazole prophylaxis, and
qualitative HIV-1 DNA PCR testing using dried blood
spot (DBS) technology. The national EID guidelines in
place during the STF project period recommended that
infant DNA PCR testing be performed as soon as possible
after 6 weeks of age [26]. Repeat DNA PCR testing was not
routinely performed during the project period, except in
cases of overdue or invalid results, or early breastfeeding
cessation (typically between infant ages of 7 to 12 months).
STF project overview
To achieve our project objectives and complement the
standard of care provided by the MoH Option B+ program,
STF implemented the following interventions, each
grounded in quality improvement (QI) methodology
and informed by nearly a decade’s worth of operational
research and situation analyses conducted by UNC in
Lilongwe: 1) training and mentorship of MoH health
workers to facilitate rapid scale up and high-quality
implementation of Option B+, EID, and other PMTCT
services; 2) promoting couples’ HTC and male partner
involvement in ANC clinic to improve the PMTCT
care-seeking environment; 3) establishing women’s
community-based psychosocial support groups to reduce
individual barriers to PMTCT service utilization; and 4)
strengthening health and laboratory systems to facilitate
early infant DNA PCR testing (Fig. 1) [18–24]. During pro-
ject year (Y) 1 (April–December 2011), we recruited STF
project personnel, including technical officers based full-
Fig. 1 Technical Approach. Safeguard the Family approach to addressing gaps along the antenatal and early postnatal prevention of
mother-to-child transmission of HIV cascade
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time in each STF district, trained MoH health workers, and
collected baseline data. During project years 2 (January–
December 2012) and 3 (January–December 2013), we
implemented STF interventions to include all 136
government health facilities located in our 5-district
catchment area.
STF catchment area and population
STF supported all government health facilities in 5 dis-
tricts of central Malawi (comprising the Central West
Zone and Dowa district), reaching a total catchment
population of 4,420,401 people in 2011 (Fig. 2) [27]. Dis-
aggregated by district, this population included 671,137,
641,895, 511,792, and 513,865 people in rural Dedza,
Dowa, Mchinji, and Ntcheu districts, respectively, and
2,081,712 people in urban and peri-urban Lilongwe [27].
On average, 51 % and 38 %, respectively, of the popula-
tion in rural STF districts and Lilongwe live on less than
$0.50 per day [28]. Based on Malawi National Statistics
Office data, there were an estimated 208,413 live births
in this population in 2011 [27, 29]. In our catchment
area and nationally, an estimated 92 % of reproductive-
age women attend at least one ANC visit [30].
Quality improvement (QI) methodology
STF employed QI methodology adapted from an approach
successfully used to scale up ART and improve PMTCT
services in South Africa [31]. STF technical and monitoring
& evaluation (M&E) officers received training and
longitudinal mentorship on basic QI methods, such as
implementing Plan-Do-Study-Act (i.e. PDSA) cycles [32].
Using these methods, STF personnel conducted collabora-
tive, facility-level QI activities with front-line MoH health
workers focused on the antenatal and early postnatal
PMTCT cascade. Field-based STF staff met with MoH
health workers at least once monthly to facilitate: 1) iden-
tification of implementation gaps at each step in the
cascade; 2) participatory compilation of proposed solu-
tions to address identified gaps; 3) iterative application
and assessment of solution effectiveness through rou-
tine M&E; 4) identification of local health worker
“focal persons” to sustain facility-level quality improve-
ment; and 5) diffusion of promising solutions through
district-wide joint mentorship visits with MoH staff.
Health worker training and mentorship
We trained 980 MoH frontline health workers, including
580 health workers on the MoH Integrated HIV Guidelines
Fig. 2 Safeguard the Family catchment area. The 5 districts within the Republic of Malawi served by Safeguard the Family (Malawi country map
source: http://www.mappery.com/Malawi-Map-2)
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(encompassing Option B+), 333 on EID, and 62 on use of
point-of-care (POC) CD4 count testing (for male partners
of women receiving couples’ HTC). We also provided data
management training to 25 MoH health information
management officers and relevant program coordinators,
based at the district health offices, who worked with facility
staff to compile and synthesize routine reporting data. To
enhance and reinforce training, we conducted 2893
mentorship and QI visits from year 2 quarter (Q) 4
through year 3 Q4. In year 2 Q4, we facilitated formation
of joint MoH-STF mentorship teams in each STF-
supported district to build MoH health worker capacity.
Each team included key PMTCT-focused coordinators
and technical staff from the respective MoH district health
offices. Mentorship teams visited each health facility in
their respective districts to provide clinical mentorship
and systems-based guidance to address logistical, patient
flow, and supply chain management challenges related to
the introduction and scale-up of Option B+. Mentorship
teams planned visits to occur with decreasing intensity,
providing intensive monthly mentorship before transition-
ing to less intensive quarterly mentorship when facilities
achieved pre-specified MoH benchmarks. These visits
complemented MoH quarterly supportive supervision per-
formed as part of the national standard of care. STF and
MoH personnel used a mentorship checklist to ensure
standardization of mentorship activities and performance
evaluations during visits. Importantly, the checklist helped
identify missing HIV commodities required for optimal
service delivery. STF responded to missing HIV com-
modities in our catchment area by providing emer-
gency supplies of HIV test kits (Alere Determine™
HIV-1/2, Waltham, Massachusetts, USA) and generic
co-trimoxazole and infant nevirapine syrup beginning
in year 2 Q2 to alleviate stock outs.
Promoting couples’ HTC and male partner involvement
To improve the PMTCT care-seeking environment, we
implemented a couples’ HTC and male partner involve-
ment intervention. This intervention encompassed: 1) 220
community mobilization talks and dramatizations to
sensitize and educate community members about the bene-
fits of early ANC, male partner involvement, couples’ HTC,
and ART for individual health and PMTCT; 2) fast-tracking
women in the HTC cue who presented to ANC clinic with
a male partner; 3) renovating infrastructure at 9 busy ANC
clinics to create dedicated HTC space; and 4) providing
same-day, POC CD4 count testing to male partners testing
HIV-positive at 16 hospitals and clinics to promote early
linkage to care and ART initiation [33]. To support our
same-day male-partner POC CD4 testing activity, we
equipped 16 health facilities with the PIMA™ CD4 Analyzer
(Alere, Waltham, Massachusetts, USA) and trained front-
line nurses, Health Surveillance Assistants (HSAs), and
HTC counselors on its use [33].
Women’s psychosocial support groups
We established 36 community-based women’s psychosocial
support groups in underserved rural areas in our catchment
area, each one linked to a nearby health center. A nurse or
HSA from the health center, or a peer health educator from
the community, led each group. An average of 20 HIV-
infected pregnant and breastfeeding mothers joined each
support group on a voluntary basis, after being sensitized to
their existence during group health talks given in ANC or
ARTclinics, or through individual HIV post-test counseling
sessions. Psychosocial support groups met monthly, provid-
ing a safe forum for HIV-infected mothers to share their
experiences and discuss issues surrounding HIV-related
stigma and discrimination, HIV-status disclosure, and ART
adherence. Support group meetings also served as a venue
for health workers to provide health education and com-
munication around breastfeeding, infant vaccination, ART
and HCC follow-up for mothers and infants, postnatal EID
services, and safe breastfeeding weaning. To incentivize
participation and support safe breastfeeding weaning, STF
provided 2 kg of vitamin-fortified soya-based porridge to
these mothers at each group meeting [23].
Strengthening health and laboratory systems in support
of EID
While national laboratory capacity for the MoH EID pro-
gram was still being built (year 2 Q1 through year 3 Q4),
STF (through the UNC laboratory in Lilongwe) performed
HIV-1 DNA PCR testing for HIV-exposed infants receiving
health services in rural Dedza, Mchinji, and Dowa districts.
During this interim period, STF also strengthened ancillary
MoH systems in these underserved districts to enable DBS
specimen transport to the Kamuzu Central Hospital (KCH)
campus in Lilongwe (site of both the KCH and UNC
laboratories) and reporting of DNA PCR test results back
to referring health facilities. Concurrently, UNC labora-
tory mentors, with U.S. Centers for Disease Control
and Prevention support, helped build MoH laboratory
capacity through pre-service training and in-service
staff mentorship on qualitative DNA PCR testing at KCH
reference laboratory. All qualitative DNA PCR testing
was performed using the Amplicor™ diagnostic platform
(Roche Diagnostics, Indianapolis, Indiana, USA).
In all project districts, STF trained MoH health workers
on the screening, enrollment, and testing of HIV-exposed
infants. Trained HTC counselors collected DBS samples for
EID testing per MoH guidelines [26]. STF staff mentored
health workers on exposed-infant identification, DBS sam-
ple collection, and proper HIV-1 DNA PCR test result
documentation and communication to mothers.
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Study design
We conducted a serial cross-sectional study to evaluate
STF performance on outcomes of interest at quarterly
intervals, and compared STF performance to national aver-
ages reported quarterly by the MoH for STF years 1
through 3 [34–44]. We compiled anonymized, cross-
sectional facility-level data to ascertain project outcomes
each quarter (Q). We employed a similar cross-sectional
approach to analyze individual-level HIV-1 DNA PCR
testing outcomes for HIV-exposed infants in the STF
catchment area.
Data collection
We collected facility-level data during quarterly field visits,
and entered the composite de-identified data into Microsoft
Excel (Redmond, Washington, USA). We abstracted data
from routine MoH and STF data-recording tools, including
an electronic data-recording system used by MoH at each
district hospital as well as paper registers and patient treat-
ment cards available in each health center to enable longi-
tudinal patient care and program M&E. We estimated
HTC uptake using data abstracted from MoH ANC regis-
ters; Option B+ uptake using MoH ANC registers; couples’
HTC uptake using MoH HTC registers; and EID provision
using MoH HCC and EID registers augmented by UNC la-
boratory information management system (LIMS) data. We
used de-identified HIV-1 DNA PCR test results abstracted
from the UNC LIMS to perform analyses in HIV-exposed
infants.
Analytical approach
Our outcomes of interest were aligned with national
PMTCT indicators, and included quarterly assessment of:
1) the proportion of pregnant women undergoing HTC
during ANC (i.e. the number of pregnant women with a
new HTC test result documented in ANC clinic / the total
number of pregnant women presenting to ANC clinic
without a prior documented positive HIV test result); 2)
the proportion of pregnant women who underwent HTC
together with a male partner (i.e. the number of pregnant
women documented to have undergone HTC with a male
partner in ANC clinic / the total number of pregnant
women documented to have received HTC in ANC
clinic); 3) the proportion of HIV-infected pregnant women
receiving combination ART during ANC (i.e. the number
of HIV-infected pregnant women documented to have re-
ceived combination ART during ANC / the total number
of pregnant women newly enrolled in ANC clinic with
either newly documented HIV infection or known prior
HIV infection); 4) the proportion of HIV-infected preg-
nant women provided with nevirapine syrup in ANC
clinic (i.e. the number of HIV-infected women with
documented receipt of infant nevirapine syrup in ANC
clinic / the total number of HIV-infected pregnant
women registered in ANC clinic); and 5) the propor-
tion of HIV-exposed infants who underwent HIV-1
DNA PCR testing (i.e. the number of HIV-exposed
infants who underwent documented DBS sample col-
lection for HIV-1 DNA PCR testing/the estimated total
number of HIV-infected pregnant women presenting
to ANC clinic). For this denominator, we used ANC
HIV prevalence data to estimate the number of HIV-
infected pregnant women among those not receiving
HTC, and added this to the number of documented
HIV-infected women registered in ANC clinic; this ap-
proach provided a more conservative estimate of EID
testing uptake. Outcome indicators estimated facility-level
utilization of HTC, couples’ HTC, maternal ART, infant
nevirapine prophylaxis, and HIV-1 DNA PCR testing, re-
spectively. For facility-level analyses, the sample size
was determined by the number of pregnant women,
HIV-infected pregnant women, and HIV-exposed
infants accessing health services in the STF catchment
area during the study period. For our individual-level
analyses of HIV-exposed infant data, we aimed to: 1)
estimate the prevalence of HIV-1 infection among
HIV-exposed infants receiving first-time DNA PCR
testing; 2) evaluate individual-level baseline infant
demographic and clinical factors associated with age at
first HIV-1 DNA PCR testing; and 3) evaluate
individual-level baseline demographic and clinical
factors associated with approximate average HIV-1
DNA PCR test result turnaround time.We approximated
test turnaround time using the following definition: time
interval in days from the date of HIV-1 DNA PCR test per-
formance to the date when mothers were notified of their
infant’s test result. For individual-level analyses, the sample
size was determined by the number of HIV-exposed infants
provided first-time HIV-1 DNA PCR testing by STF during
the study period.
Data analyses
We present descriptive statistics for all facility- and
individual-level outcomes, including frequencies, percent-
ages, and 95 % confidence intervals for categorical variables,
and mean, median, and measures of dispersion for continu-
ous variables. We compared proportions for facility-level
PMTCT outcome indicators at baseline and end-of-project
using the two-sample test of proportions. We compared
median approximate test turnaround time and infant age at
first HIV-1 DNA PCR testing using the Wilcoxon Rank-
Sum test. We restricted our analyses to individuals with
complete data for all variables required to conduct a par-
ticular analysis and, in the case of indicator calculations, to
individuals with a documented outcome event. All statis-
tical analyses were performed using SAS version 9.2 (Cary,
NC, USA) and STATA version 12.1 (College Station, TX,
USA).
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Results
Overview
We first report facility-level outcome indicators for
513,098 newly registered ANC attendees (both HIV-
positive and HIV-negative pregnant women) served by
STF over its 33-month project lifespan, including
141,519, 189,915, and 177,709 pregnant women acces-
sing facility-based ANC services in years 1 through 3, re-
spectively. We then present our individual-level analyses
of HIV-1 DNA PCR test results for HIV-exposed infants.
HIV testing and counseling
Over the entire project period, 1.6 % (n/N = 8,441/
513,098) of ANC attendees were known to be HIV-
infected at the time of ANC enrollment. Quarterly up-
take of HTC among ANC attendees without a docu-
mented positive HIV test result in the preceding
3 months increased significantly from a baseline of 66 %
(n/N = 32,433/48,804) to 87 % (n/N = 39,458/45,324) by
project end (p < 0.001) (Fig. 3). Conversely, the annual
proportion of eligible pregnant women who did not receive
HTC for any reason during their first ANC visit decreased
significantly from 37 % in year 1 (n/N = 51,332/139,259) to
17 % in year 3 (n/N = 28,927/174,492) (p < 0.001). After
below average performance in year 1, STF-supported dis-
tricts slightly outperformed the quarterly national average
(mean difference: 0.4 %) for HTC uptake in ANC clinic
during project years 2 and 3 (Fig. 3).
In project year 1, 21 % (n/N =18,137/86,799) of pregnant
women received facility-based couples’ HTC. In project
year 3, 30 % (n/N = 43,595/145,721) of pregnant women
accessing HTC in ANC underwent HTC accompanied by a
male partner (Fig. 4). The proportion of pregnant women
who underwent facility-based couples’ HTC increased sig-
nificantly from project start (Y1) to end (Y3) (p < 0.001).
The prevalence of documented HIV infection among
pregnant women who underwent HTC in ANC clinic de-
creased significantly from the start to end of STF—from a
baseline of 6.4 % (95 % confidence interval, CI: 6.3–6.6 %;
n/N = 5,725/89,059) in year 1 and 6.4 % (95 % CI: 6.2–
6.5 %; n/N = 7,429/116,290) in year 2 to 5.7 % in year 3
(95 % CI: 5.6–5.8 %; n/N = 8,448/148,938) (p < 0.001).
Combination ART in ANC
Prior to Option B+ (in Y1 Q2), combination ART quarterly
uptake among HIV-infected pregnant women in the STF
catchment area was 23 % (n/N = 442/1,958). Following STF
health worker trainings that enabled Option B+ roll out to
Fig. 3 HIV testing & counseling (HTC) uptake. Quarterly comparison of antenatal clinic HTC uptake in the Safeguard the Family catchment area
compared to the national average for project years 1 to 3 (April 2011 through December 2013)
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82 % of health facilities in our catchment area by year 1
end, quarterly ART uptake among HIV-infected pregnant
women presenting to ANC increased significantly to 66 %
(n/N = 1,057/1,600) by Y1 Q4 (p < 0.001) and 96 % (n/N =
2,046/2,121) by Y3 Q4 (p < 0.001), compared to the pre-B+
baseline (Fig. 5). Over the project lifespan, mean quarterly
ART uptake in STF-supported districts (74 %) mirrored the
national average (75 %). During project years 2 and 3, how-
ever, STF-supported districts outperformed the quarterly
national average (mean difference: 1.6 %) (Fig. 5).
Infant nevirapine prophylaxis
Provision of infant nevirapine prophylaxis to mothers in
ANC clinic improved each quarter over the project lifespan
(Fig. 6). At baseline (Y1 Q2), 1 % (n/N = 10/1,958) of HIV-
infected pregnant women presenting quarterly to ANC re-
ceived nevirapine syrup for infant HIV prophylaxis (Fig. 6).
By project end, this had increased significantly to
100 % (n/N = 2,121/2,121) (p < 0.001). During years 2
and 3, STF outperformed the quarterly national aver-
age by a mean difference of 18 %.
Fig. 4 Couples’ HIV testing & counseling (HTC) uptake. Annual uptake of couples’ HTC in the Safeguard the Family catchment area for project
years 1 to 3 (April 2011 through December 2013)
Fig. 5 Option B+ uptake. Quarterly comparison of maternal combination antiretroviral therapy / Option B+ uptake among HIV-infected pregnant
women presenting to antenatal care clinics in the Safeguard the Family catchment area compared to the national average for project years 1 to
3 (April 2011 through December 2013)
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Early infant diagnosis of HIV infection
The proportion of HIV-exposed infants who had a DBS
sample collected in a quarter for first-time HIV-1 DNA
PCR testing in STF-supported districts increased signifi-
cantly from a Y2 Q1 baseline of 52 % (n/N = 1,385/2,644)
to 62 % (n/N = 1,462/2,340) by Y3 Q4 (p < 0.001). By
project year, uptake increased significantly from 46 %
(n/N = 5,488/11,916) in year 2 (the first full year that the
MoH EID program was implemented in STF districts)
to 57 % (n/N = 5,773/10,089) in year 3 (p < 0.001).
STF provided interim first-time HIV-1 DNA PCR
testing for 2,226 of the 11,261 HIV-exposed infants
(20 %) who underwent DBS sample collection in the
MoH EID program in our catchment area from pro-
gram inception (Y2 Q1) through the end of year 3. Of
the 2,226 total HIV-exposed infants we tested, 78 were
found to be DNA PCR positive for HIV-1 (3.5 %). Dur-
ing year 3 (the only year with national EID data available
for comparison), a non-significantly lower proportion of
HIV-exposed infants (3.6 %) tested HIV-infected at first
testing in STF districts compared to the national average
(4.1 %) (p = 0.4). Twenty-seven percent (n/N = 608/2,226)
of HIV-exposed infants had both a date of birth and DNA
PCR test date documented. The median age at the time of
HIV-1 DNA PCR testing for these 608 infants was 83 days
(IQR: 48–166). On average, infants found to be HIV-1
positive underwent first DNA PCR testing at an older
age (median: 162 days, IQR: 63–221) than infants test-
ing negative (median: 82 days, IQR: 48–164) (p = 0.05).
Among HIV-exposed infants with complete EID
documentation (n = 608), median age at first DNA PCR
testing decreased significantly (p <0.001) from 112 days
(IQR: 57–198) in year 2 to 76 days (IQR: 46–152) in
year 3.
Sufficient documentation was available for 560 infants to
determine the approximate average HIV-1 DNA PCR test
result turnaround time. For this subgroup, median turn-
around time was 49 days (IQR: 32–78 days). We observed
no significant difference in approximate turnaround time
by HIV-1 DNA PCR test result status (HIV-1 positive:
62 days; HIV-1 negative: 49 days, p = 0.3).
Discussion
We report high facility-level utilization of HTC, ART,
and infant nevirapine prophylaxis, and moderate EID
services uptake in five Malawi districts supported by
STF interventions. STF interventions enhanced the
standard of care offered by the national Option B+ pro-
gram, addressed some health sector needs along the
antenatal and early postnatal PMTCT cascade, and con-
tributed to a low proportion of HIV-exposed infants
found HIV-1 positive at first DNA PCR testing. Perform-
ance on national facility-level PMTCT indicators in STF
districts improved by project end, and compared favor-
ably with national averages.
Previous reports of PMTCT programs in Malawi and
elsewhere in SSA—prior to Option B +—highlighted
several service delivery gaps in the PMTCT cascade,
including low uptake of HTC, suboptimal provision of
ART to qualifying HIV-infected pregnant women, and
Fig. 6 Infant nevirapine prophylaxis uptake. Quarterly comparison of infant nevirapine prophylaxis uptake among HIV-infected pregnant
women presenting to antenatal care clinics in the Safeguard the Family catchment area compared to the national average for project years
1 to 3 (April 2011 through December 2013)
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inadequate HIV testing among HIV-exposed infants
[13, 45–48]. In a recent meta-analysis from SSA, only
70 % of pregnant women received some form of antiretro-
viral prophylaxis and 40 % of eligible women did not
initiate ART [45]. Historically, women have also faced
challenges accessing HIV care for their HIV-exposed
infants [12, 49]. In Malawi, for example, in a cohort of
14,669 HIV-infected pregnant women and their HIV-
exposed infants seeking care in Lilongwe from 2004 to
2008, only 54 % of infants underwent HIV DNA PCR test-
ing, and 14 % of these infants were found to be HIV-
infected [12].
In the context of these challenges, we achieved favor-
able outcomes compared to both national averages and
baseline outcome indicators in STF districts. Several rea-
sons may explain the results observed. First, the public
health approach taken by the MoH Option B+ program in
improving access to maternal ART and infant nevirapine
prophylaxis, led to an increased number of women and
infants receiving an efficacious PMTCT regimen in our
catchment area [14, 50]. Second, the application of basic QI
methodology empowered health workers to identify locally
relevant strategies to optimize facility-level processes for
HTC, ART, and EID service delivery. For example, the
establishment of EID “focal persons” responsible for over-
seeing HIV-exposed infant enrollment and DNA PCR test-
ing in each clinic—an idea first generated from a
collaborative QI exercise at Dowa District Hospital and
later implemented in all STF districts—may help explain
the increased uptake and reduction in median age at first
DNA PCR testing observed among HIV-exposed infants
over the project period. Third, health worker training and
intensive mentorship provided by STF on PMTCT service
delivery, including Option B+, may have contributed to
more guideline-adherent care and rapid dissemination of
best practices. Mounting evidence suggests that longitu-
dinal, structured clinical mentorship contributes to im-
provements in health-system performance indicators and
clinical outcomes, particularly for maternal and child health
[51–53]. Fourth, the high uptake of HTC observed may be
explained by implementation of opt-out HTC, couples’
HTC, and male partner involvement strategies in ANC
clinics. Use of opt-out HTC has been shown to be an effect-
ive strategy for increasing HTC utilization in resource-
limited settings [18, 54, 55]. Similarly, couples’ HTC and
male partner involvement strategies have been associated
with beneficial clinical outcomes and health behaviors in
SSA, including increased care seeking behavior among
HIV-infected women, improved outcomes for HIV-exposed
infants, and greater opportunities for linkage to care for
HIV-infected men who may be less likely to access HIV ser-
vices otherwise [33, 56–58]. Fifth, psychosocial support
groups for HIV-infected pregnant women may have par-
tially reduced barriers to PMTCT services by ameliorating
HIV-associated stigma and encouraging uptake of HTC,
ART, and EID services [59]. Lastly, investments in public-
sector EID laboratory and ancillary systems, and direct
provision of infant HIV-1 DNA PCR testing by STF during
EID scale-up may have contributed to the moderate uptake
of testing seen among HIV-exposed infants.
We observed an increase in the proportion of HIV-
exposed infants receiving DNA PCR testing and earlier
uptake of EID testing services over time. However, en-
suring high uptake of early HIV-1 testing for all exposed
infants in our project area was challenging. In a
subgroup of infants with complete documentation, we
observed that the median age at first DNA PCR testing
was approximately 12 weeks, nearly 6 weeks later than
the age recommended by national guidelines. We attri-
bute this to persistent gaps in health worker EID train-
ing, DBS sample collection, exposed-infant registration,
and exposure screening among infants born at home
who later present for routine health services. Infants
found to be HIV-infected received DNA PCR testing
even later, at an average of almost 6 months of age.
While this result may simply reflect the increased HIV-
acquisition risk that comes with prolonged breastfeeding
duration, the presence of important concomitant barriers
to health services utilization cannot be excluded in this
sub-group. Even after HIV-exposed infants access EID
testing services, health system inefficiencies create delays in
providing critical test results to patients and front-line
health workers. Among HIV-exposed infants with complete
records, the time from DNA PCR testing to result notifica-
tion for families and healthcare providers was 49 days.
Resource limitations and logistical barriers within district-
level laboratory and ancillary systems likely contributed to
the delays experienced by end-users in receiving timely
DNA PCR test results. To address these issues, renewed
focus is required to fill persistent gaps in EID services
by ensuring an uninterrupted supply of EID laboratory
reagents, moving away from paper-based DNA PCR test
result notification systems to SMS and web-based plat-
forms, and enhancing community-facility linkages to
improve post-natal mother-infant pair follow-up and re-
tention in care. Indeed, scale up and further evaluation
of promising community-facility linkage strategies are
urgently needed to overcome pervasive challenges with
client transport and other structural barriers to care that
contribute to delayed service utilization and mother and
infant loss to follow-up in Option B+ programs in SSA
[8, 10, 60]. The Malawi MoH and implementing part-
ners are committing new resources and evaluating novel
strategies—including community health worker sup-
port, motorcycle-rider laboratory couriers, POC nucleic
acid-based HIV testing, and active tracing of HIV-
infected mothers and exposed infants who have fallen
out of care—to improve the proportion of exposed
Herce et al. BMC Infectious Diseases  (2015) 15:328 Page 10 of 13
infants receiving HIV-1 testing by 2 months of age such
that all HIV-infected infants access timely ART [61, 62].
While we demonstrated that facility-level PMTCT service
utilization improved over time in our catchment area, and
outperformed some important national PMTCT indicators
by the end of STF, other factors in addition to STF inter-
ventions may explain the results we observed. Such factors
include health system strengthening investments and/or
PMTCT activities conducted by other implementing
partners and non-governmental organizations (NGOs)
in STF districts. Notably, strong partnerships between
MoH and implementing partners also existed in other re-
gions of the country, so the comparisons we made to na-
tional indicators were to national Option B+ program
outcomes that were also NGO-supported. In addition to
the possible influence of external factors, our study had sev-
eral other limitations. First, we were unable to estimate
PMTCT service utilization among HIV-infected women
who did not have at least one ANC clinic visit or who did
not undergo facility-based HTC. An estimated 8 % of
pregnant women did not have an ANC clinic visit dur-
ing the project period, and over one-third of ANC
attendees did not undergo HTC in years 1 and 2 largely
due to HIV test kit shortages pervasive in Malawi at the
time [35, 63, 64]. This may have led our facility-level in-
dicators to overestimate true service utilization in the
population of HIV-infected pregnant women and ex-
posed infants in our catchment area. Second, while we
provided HIV-1 DNA PCR testing to over 2,000 HIV-
exposed infants, this represented just 20 % of the total
number of infants undergoing testing in our catchment
area during the project period, limiting the generalizability
of our findings about STF impact on early MTCT. Third,
the cross-sectional nature of our facility-level indicators
prevented us from drawing inferences about the effects of
STF interventions on individual-level maternal and infant
outcomes over time, including the proportion of HIV-
infected infants linked into HIV care and treatment. To ad-
dress these issues, additional studies in central Malawi are
ongoing using linked, mother and infant cohort data to
understand the patient-level factors associated with vertical
HIV transmission under routine operational conditions,
and to estimate the adjusted individual-level risk of loss to
follow up for Option B+ clients and newly diagnosed HIV-
infected infants in STF-supported districts.
Conclusions
We describe STF interventions, integrated within the
national Option B+ program, that addressed gaps along
the antenatal and early postnatal PMTCT cascade and
that strengthened PMTCT services for over half a mil-
lion pregnant women in central Malawi. We note high
facility-level utilization of HTC, ART, and infant nevirapine
prophylaxis, and moderate uptake of EID services in STF
districts, comparing favorably to national averages and dif-
fering from prior reports of inadequate service delivery and
low PMTCT service uptake in SSA. We speculate that by
enhancing the national Option B+ program, STF interven-
tions contributed to the lower proportion of HIV-exposed
infants found HIV-1 positive at first DNA PCR testing in
STF districts compared to the national average. Several STF
interventions, including health worker mentorship, facility-
level QI, and couples’ HTC, have since influenced or been
adopted by the national Option B+ program to strengthen
the PMTCT cascade throughout Malawi, suggesting the
scalability and sustainability of our approach. Lastly, we re-
port findings from an individual-level analysis of infant
DNA PCR test results in which we observed progressive re-
ductions in the age at first testing over the STF project
period, despite ongoing challenges of prolonged result turn-
around times and delayed first DNA PCR testing. To ad-
dress these challenges and to build upon the early success
of Option B+ in Malawi, governmental and non-
governmental partners should reaffirm their commitment
to improving EID services and continue to invest in ameli-
orating gaps along the PMTCTcascade.
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